The sales rep study I’d like to see

We’re not sure what to make of a just-released JAMA study* by two professors of, respectively, business management, and economics and psychology, after a highly detailed study of the prescribing practices at academic medical centers. The goal was to compare […]

Read More

2017 Product Security Report

Pharmaceutical Commerce has used the term ‘Year Zero’ in talking about 2017 and the deadlines for compliance with the US Drug Supply Chain Security Act, simply because the key next step—having a unique serial number on each package of product […]

Read More
| 1 Comment

New science energizes the cancer market

Oncology drugs have had a prominent position in the biopharma industry, as well as healthcare generally, because the stakes are so high: cancer is often fatal; in its many forms, it is a common health condition; and, in recent years, […]

Read More

A Conversation with John Chiminski, Catalent

In April, Catalent, Inc., celebrated its 10th anniversary of its inception, having been spun out of Cardinal Health in 2007 and acquired by Blackstone Group, a private-equity firm. Later, in 2014, the company went public, traded on the NYSE. Both […]

Read More